WEMADE
11.1.2024 10:10:28 CET | Business Wire | Press release
Global pre-registration for ‘NIGHT CROWS’, a game published by Wemade and developed by MADNGINE, began on January 11th.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240110750299/en/
Wemade opens global pre-registration for ‘NIGHT CROWS’ (Graphic: Wemade)
NIGHT CROWS is an MMORPG based on Unreal Engine 5 that supports cross-play between mobile and PC platforms. Realistic light source illumination and high-quality graphics, 4 classes and 8 sub-classes that amplify user choice and effort, Dynamic combat encompassing ground and air using Gliders, Large-scale war from 1,000 players in realistic and vast fields in ”Battlefront” content, and more are included in the game. After its release in the Republic of Korea in April 2023, the game reached No. 1 in most downloads and top sales charts in major mobile app markets.
Pre-registration will be open until the official launch in March on the official website, Google Play, and Apple App Store. Abundant pre-registration rewards include a rare-grade Mount, Glider, and more.
Wemade has utilized blockchain technology to implement multi-tokenomics with the tokenization of core in-game items in NIGHT CROWS. The in-game economy will also be interconnected with Character NFTs, each NFT created through the compression of the character and user's game data.
As the game will be connected with WEMIX3.0 at the center following an omnichain network strategy, users of other blockchain networks will be able to easily utilize the tokenomics as well.
Also implemented will be the “SSS (Streamer Supporting System).” SSS is a transparent support system in which users of Wemade games, Streamers who create content related to Wemade games, and Supporters who support Streamers can co-exist. Pre-registration rewards for SSS Streamers include a rare-grade Glider with special looks.
Additionally, the NFT Collection ‘The Night is Coming’ will be sold in celebration of pre-registration on the WEMIX3.0-based DAO & NFT platform ‘NILE’ (NFT Is Life Evolution) starting today. The NFTs may be exchanged with ‘CROW,’ the key token of NIGHT CROWS, from April 1st.
At Taipei Game Show 2024, Wemade will be presenting the demo version of NIGHT CROWS. The show will be held at the Taipei Nangang Exhibition Center from January 25th to 28th.
Information on NIGHT CROWS can be found on the official website.
Website references
NIGHT CROWS Official website: https://nightcrows.com/preregister
NEITH NFT ‘The Night is Coming’ Preview: https://medium.com/nile-official/neith-nft-the-night-is-coming-preview-bd75718daa08
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240110750299/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom